The agenda for this unique meeting has been designed to provide practical perspectives on current and emerging treatment strategies. Each module will feature discussion of cases submitted on video by practicing general oncologists followed by a faculty presentation reviewing relevant data sets and promising investigational approaches.

MODULE 1: Biomarker Assessment and Selection of Therapy for Patients with Newly Diagnosed Metastatic Colorectal Cancer (mCRC) — Dr Grothey

Topics to be reviewed during case discussion and faculty presentation

• Effect of primary tumor sidedness on prognosis and systemic treatment decision-making
• Role of tissue testing, including RAS, BRAF and microsatellite instability (MSI)
• Prevalence and prognostic significance of various BRAF mutations among patients with advanced CRC; effects, if any, of a BRAF V600E mutation on current nonresearch decision-making
• Frequency of HER2 amplification in patients with mCRC; indications for HER2 testing and nonresearch role of anti-HER2 therapy
• Considerations for systemic perioperative therapy in patients with oligometastatic disease

MODULE 2: Clinical and Palliative Care Considerations for Patients with Progressive mCRC — Prof Van Cutsem

Topics to be reviewed during case discussion and faculty presentation

• Clinical decision-making for patients with disease progression on front-line chemobiologic therapy: Importance of RAS status, prior therapy, disease-free interval, performance status (PS) and other factors in the selection of second- and later-line therapy
• Optimal sequencing of regorafenib and TAS-102 for patients with mCRC; use of clinical characteristics to inform this decision (eg, PS, hematologic reserve)
• Clinical investigator perspectives on initial dosing and dose reduction or escalation strategies with regorafenib
• Incidence and time course of common toxicities associated with regorafenib and TAS-102
• Clinical trials evaluating TAS-102 and regorafenib as earlier-line therapy
• Role, if any, of multiplex testing (ie, next-generation sequencing) after disease progression on multiple lines of therapy

MODULE 3: Existing, Recently Approved and Investigational Approaches for Patients with Pancreatic Adenocarcinoma (PAD) — Dr Chiorean

Topics to be reviewed during case discussion and faculty presentation

• Available data with and current clinical indications for the use of nab paclitaxel/gemcitabine and FOLFIRINOX as (neo)adjuvant therapy
• Importance of age, PS, comorbidities and patient preferences in the selection of first-line chemotherapy for metastatic PAD
• Nanoliposomal formulation of nal-IRI and proposed effects on drug delivery and efficacy
• Phase III efficacy and safety data with, patient selection for and practical integration of nal-IRI in relapsed disease
• Promising agents and treatment strategies currently in development

MODULE 4: Novel Agents and Strategies in the Management of Hepatocellular Carcinoma (HCC) — Dr El-Khoueiry

Topics to be reviewed during case discussion and faculty presentation

• Prevention, recognition and management of side effects associated with sorafenib in HCC
• Sorafenib dosing in unique populations (Child-Pugh class B or C, elderly, poor PS)
• Emerging results from the Phase III Study 304 comparing lenvatinib to sorafenib as first-line therapy for unresectable HCC
• FDA approval of regorafenib as second-line therapy for patients with HCC progressing on sorafenib; optimal integration into current management algorithms
• Early efficacy data with, current nonresearch role, if any, of and ongoing trials evaluating anti-PD-1/PD-L1 antibodies for patients with advanced HCC

MODULE 5: Protocol and Nonresearch Treatment Decision-Making for Patients with Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer — Dr Fuchs

Topics to be reviewed during case discussion and faculty presentation

• Sequence and selection of systemic therapy for patients with newly diagnosed and progressive metastatic disease: Implications of HER2 status, prior (neo)adjuvant therapy, age/PS and disease-free interval
• Evidence-based integration of ramucirumab into the clinical algorithms for metastatic gastric/GEJ cancer; ongoing Phase III clinical trials of ramucirumab (eg, RAINFALL)
• Available safety and efficacy data with anti-PD-1/PD-L1 antibodies for advanced gastric/GEJ cancer (eg, ATTRACTION-2); current role, if any, in clinical practice
• Ongoing trials evaluating immune checkpoint inhibitors in gastric/GEJ cancer
• Biologic rationale for, early clinical trial data with and ongoing investigation of novel agents and strategies (eg, napabucasin, claudiximab, TAS-102, regorafenib)

MODULE 6: Potential Role of Immune Checkpoint Inhibitors in Patients with mCRC —
Dr Overman

Topics to be reviewed during case discussion and faculty presentation

• Biologic function of DNA mismatch repair and consequences of its deficiency; MSI and hypermutability of cells
• Incidence of MSI-high tumors in patients with CRC and other gastrointestinal cancers
• Indications and guideline recommendations for MSI testing in patients with mCRC
• Biologic rationale for responsiveness of MSI-high tumors to anti-PD-1/PD-L1 checkpoint inhibitors
• Available data, current clinical role, if any, and ongoing trials with anti-PD-1/PD-L1 antibodies for MSI-high cancer
• Clinical strategies under investigation to induce immune responses in patients with microsatellite stable CRC